NutriMost LLC – Trademark Portfolio

Entity Type: 16

NutriMost LLC holds 44 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 41 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include NUTRIMOST, ADRENAMOST, and HYDROMOLECULAR. The owner is based in Murrysville, PA.

135 Bella Vista Ct.

Murrysville, PA 15668

44 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (44 results)

Trademark Classifications

NutriMost LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (41 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (4 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does NutriMost LLC have?

NutriMost LLC has 44 U.S. trademarks filed with the USPTO. Of these, 3 registered, 19 abandoned, 22 cancelled.

What trademark classes does NutriMost LLC file in?

NutriMost LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NutriMost LLC's most well-known trademarks?

NutriMost LLC's registered trademark portfolio includes well-known marks such as NUTRIMOST, ADRENAMOST, and HYDROMOLECULAR. These are among 3 currently registered trademarks in the portfolio.

What is NutriMost LLC's trademark registration success rate?

NutriMost LLC has a 7% trademark registration rate, with 3 out of 44 resolved applications resulting in successful registration. Currently, 0 applications are pending review.